Opendata, web and dolomites

4-IN THE LUNG RUN SIGNED

4-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 4-IN THE LUNG RUN project word cloud

Explore the words cloud of the 4-IN THE LUNG RUN project. It provides you a very rough idea of what is the project "4-IN THE LUNG RUN" about.

discuss    copd    benefits    practices    dutch    limited    effectiveness    stakeholders    innovative    healthcare    unknown    devastating    innovation    score    individuals    interval    intensive    negative    services    integrate    cessation    morbidity    quality    prevent    billion    annually    intervals    international    reducing    history    savings    regimens    settings    lung    hard    interact    thoracic    cancer    belgian    ten    strategies    easily    recruit    slow    harm    health    strategy    retain    ct    participation    personalised    screening    smoking    saving    steer    model    mortality    achievable    25    natural    24    calcium    form    outcomes    referral    co    rates    nelson    conclusive    euros    screens    safe    interim    unnecessary    usa    with    optimal    guidelines    randomised    amongst    85    potentially    nlst    run    million    deaths    huge    338    regarding    trial    biomarkers    markers    thousands    tested    risk    relatively    base    baseline    imaging    45    heart    positive   

Project "4-IN THE LUNG RUN" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 7˙999˙948 €
 EC max contribution 7˙999˙948 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 1˙926˙250.00
2    INSTITUTE FOR DIAGNOSTIC ACCURACY RESEARCH BV NL (GRONINGEN) participant 1˙901˙500.00
3    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI IT (Milan) participant 1˙398˙500.00
4    DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG DE (HEIDELBERG) participant 677˙443.00
5    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 591˙240.00
6    INSTITUT CATALA D'ONCOLOGIA ES (L'HOSPITALET DEL LLOBREGAT) participant 526˙575.00
7    INSTITUT GUSTAVE ROUSSY FR (VILLEJUIF) participant 425˙750.00
8    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 368˙470.00
9    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 184˙220.00

Map

 Project objective

With 338,000 EU-deaths annually, lung cancer is a devastating problem. CT screening has the potential to prevent ten-thousands of lung cancer deaths annually. The positive results of the Dutch-Belgian screening trial (NELSON), with relatively low referral rates, and the NLST in the USA provided conclusive evidence. However, implementation is likely to be limited, slow and of variable quality throughout Europe, and current guidelines could easily require up to 25 million CT screens annually. The most optimal strategy in risk-based lung-thoracic screening is still unknown regarding the optimal and most cost-effective (e.g., targeted) strategy 1) to recruit, 2) to integrate smoking cessation and co-morbidity-reducing services, and 3) to determine the (risk-based) screening interval. Personalised regimens based on the baseline CT result can potentially retain 85% of the mortality reduction achievable through screening at 45% less screens, thus potentially saving much unnecessary harm associated with screening, and 0.5-1 billion Euros per year. The heart of 4-IN-THE-LUNG-RUN is a randomised controlled trial amongst 24,000 individuals evaluating whether it is safe to have risk-based less intensive screening intervals after a negative baseline CT. Various methods to improve participation of hard-to-reach individuals will be assessed in five different healthcare settings. Innovative co-morbidity reducing strategies will be tested including other markers on CT imaging, as Calcium Score and COPD. Cost impact and cost-effectiveness analyses using a natural history model will steer implementation. The experienced consortium will strongly interact with key stakeholders, and discuss interim results with key other international initiatives on CT screening, biomarkers, and smoking cessation practices. This proposal will form the evidence base for risk-based lung cancer screening with huge benefits for the EU, on health outcomes, cost savings, and innovation in the long run.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "4-IN THE LUNG RUN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "4-IN THE LUNG RUN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

HEAP (2020)

Human Exposome Assessment Platform

Read More  

EXIMIOUS (2020)

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

Read More